Fact checked byMindy Valcarcel, MS

Read more

March 23, 2024
1 min read
Save

Colorectal Cancer Awareness Month: Insights into early-onset disease, impact of diabetes

Fact checked byMindy Valcarcel, MS
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

March is Colorectal Cancer Awareness Month.

An estimated 152,810 new cases of colorectal cancer will be diagnosed in the United States this year, according to American Cancer Society. Approximately 53,010 people will die of the disease, society statistics show.

Colon cancer

An estimated 152,810 new cases of colorectal cancer will be diagnosed in the United States this year, according to American Cancer Society. Image: Adobe Stock

In conjunction with Colorectal Cancer Awareness Month, Healio provides the following updates about advances in prevention, diagnosis and treatment.

1. Despite a decline in overall incidence of colorectal cancer in the U.S., population-based data from American Cancer Society show an alarming shift to younger age and more advanced disease at diagnosis. Read more.

2. Researchers at Cleveland Clinic identified differences in tumor-related bacteria that may improve understanding of young-onset colorectal cancer. The findings could lead to new screenings or treatment approaches for this population. Read more.

3. Sex also may be a contributing factor to early onset colorectal cancer, as researchers reported a sharper increase since 1988 among men but not women. Read more.

4. More than 10% of fecal immunochemical tests used for routine colorectal cancer screening contained unsatisfactory samples that could not be processed. Read more.

5. Risk for colorectal cancer increased by 47% among individuals with type 2 diabetes. Read more.

6. Diabetes also appeared associated with poorer outcomes after curative resection for colorectal cancer. Read more.

7. Glucagon-like peptide 1 receptor agonists significantly lowered the risk for colorectal cancer in patients with type 2 diabetes compared with other diabetes medications. Read more.

8. Circulating tumor DNA-based detection of molecular residual disease appeared to be highly prognostic of patient outcomes. Read more.

Reference: